Shots:

• Atriva will commence P-II study assessing ATR-002 vs PBO in hospitalized patients with moderate COVID-19- expected to be initiated in July’2020
• ATR-002’s MOA inhibits SARS-CoV-2 viral propagation and prevents the cytokine storm as demonstrated in its preclinical studies. The dual antiviral and immunomodulatory effect allows the therapy to prevent progression to critical-stage COVID-19 in hospitalized patients
• ATR-002 is a MEK inhibitor targeting the intracellular Raf/MEK/ERK signaling pathway and has the potential to modulate the pro-inflammatory cytokine response of the body- thus avoiding overshooting cytokine response. The company has filed respective patents with the European Patent Office

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Atriva